Aim of this study is improvement of survival and quality of life after radical surgery for gastrointestinal cancer using drug delivery system.
1) When P388 murine leukemic cells (5x10_5/0.05ml of normal saline) were inoculated subcutaneously into the left hind footpad of BDF1 mice, they transferred to the left popliteal and the left lumber lymph nodes within 8 days. AT this time various combinations of MMC,Ok-432 and CH40 were injected into the left popliteal lymph nodes, and 3 hours after, the left hind foot were removed. Six days after, the left lumbar lymph node was transplanted into the peritoneal cavity of a recipient mouse and survival curves for the recipients were evaluated. The injection of a mixture of MMC,OK-432, and CH40 into lymph nodes enhanced survival.
2) The data of 1602 patients with gastric cancer who underwent radical gastrectomy were reviewed by multivariate analyzes using computer. As a result, intra-lymph node injection of MMC-CH-OK should be indicated to patients who have cancer with submucosal or muscular invasion.
3) A randomized clinical trial was started. Patients with gastric cancer whose cancer were diagnosed submucosal or muscular invasion, underwent injection of MMC-CH-OK or CH into perigastric lymph nodes during surgery and radical gastrectomy. 67 patients were classified into the MMC-CH-OK group and 68 patients were classified into the CH group. Survival of MMC-CH-OK group was slightly higher than that of CH group. However, the difference was not statistically significant.